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lzheimer’s disease is the commonest cause of
dementia and describes a clinical syndrome made up of
three domains. First, a neuropsychological domain
encompassing those deficits of cognitive function such as
amnesia (memory loss),aphasia (language disturbance),
apraxia (the inability to carry out motor tasks despite
intact motor functions),and agnosia (the inability to rec-
ognize people or objects despite intact sensory func-
tions). Second, a group of psychiatric symptoms and
behavioral disturbances,which have been termed neu-
ropsychiatric features,
1 noncognitive phenomena, or
behavioral and psychological symptoms of dementia
(BPSD).
2These consist of psychiatric symptoms (such as
delusions,hallucinations,depression,paranoid ideas,and
misidentifications) and behavioral disturbances (such as
aggression,wandering,and sexual disinhibitions).Third,
problems with activities of daily living (ADL), which
include instrumental ADL in the early stages of demen-
tia when the person is unable to carry out complex tasks,
such as shopping,driving,and using the telephone,and
basic ADL in the later stages of dementia,when a person
is unable to go to the toilet or feed,dress,and wash them-
selves.
Causes of dementia
The relative frequency of causes of dementia vary
depending on the population under study.Alzheimer’s
disease is probably the commonest form (about 50%),
followed by vascular dementia (about 25%) and demen-
tia with Lewy bodies (about 20%), with the other 5%
being made up of reversible dementias and rarer forms
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In Alzheimer’s disease, cognition now responds to several
drugs. Anticholinesterases target the acetylcholine deficit.
In mild-to-moderate Alzheimer’s disease, they all provide
significant benefit versus placebo on the Alzheimer’s
Disease Assessment Schedule–Cognitive Section (ADAS-
Cog). Side effects, in 5% to 15% of cases, include nausea,
vomiting, diarrhea, anorexia, and dizziness. Tacrine, the
leading anticholinesterase, caused frequent hepatic enzyme
elevation and was withdrawn; once-daily donepezil spares
the liver and improves global measures of change in severe
dementia; rivastigmine is indicated in comorbid vascular
disease; while galantamine modulates the cerebral nico-
tinic acetylcholine receptors that potentiate the response
to acetylcholine. Alternative agents include the N-methyl-
D-aspartate (NMDA) receptor antagonist, memantine,
licensed in Europe for moderately severe to severe
Alzheimer’s disease; it acts on a different neurotransmit-
ter system present in 70% of neurons, protecting against
pathologic glutamergic activation while preserving or
even restoring physiologic glutamergic activation. The
clinician’s armamentarium in AD has never been greater.
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of dementia, such as frontal lobe dementia or
Creutzfeldt-Jakob disease.There is increasing evidence
that there is a significant overlap between the two com-
monest causes—Alzheimer’s disease and vascular dis-
ease.Clinically,it is common for individuals to have fea-
tures of both disorders.Epidemiological studies suggest
that the risk factors for vascular disease are also associ-
ated with the development of Alzheimer’s disease.
3
Histological studies have shown that in many patients
there is a coexistence of vascular and Alzheimer’s
changes and that, even in the presence of Alzheimer’s
disease histologically,vascular changes significantly influ-
ence the clinical picture in terms of the presence of
dementia.
4
Assessment of dementia
There are now a number of established standardized
tools for the assessment of features of dementia and
measurement of change.
Cognitive function
Cognitive function is at the core of the assessment of
Alzheimer’s disease.The most widely used assessment is
the Alzheimer’s Disease Assessment Schedule—
Cognitive Section (ADAS-Cog
5),which assesses a num-
ber of domains in addition to memory and is sensitive to
change. Scores range from zero (no impairment) to 70
(severe impairment).Generally speaking,patients with
mild-to-moderate Alzheimer’s disease show an increase
in ADAS-Cog scores of between 6 to 12 points a year
(the ADAS-Cog is scored in the same way as the original
Blessed Scale,
6 which measures the number of errors
rather than the number of correct answers, hence a
higher score indicates better cognitive function,in dis-
tinction to most other tests).In the later stages of demen-
tia,the Severe Impairment Battery
7 is able to measure
cognitive function with a score from zero to 100.
8 The
Mini-Mental State Examination (MMSE)
9 is also used as
both a measure of change and a descriptor of the sever-
ity of the illness (scores of less than 10 out of 30 equate
with severe dementia, 10-18 with moderate dementia,
and 18-23 mild dementia;scores of 24 and above indicate
normality).
Neuropsychiatric features
Neuropsychiatric features have been included in studies
more recently as recognition of their importance grows.
One of the most popular assessments is the Neuropsy-
chiatric Inventory (NPI),
1 which is a 12-item scale that
measures a range of noncognitive features. Ratings of
frequency and severity are included giving a total score
of 144.
Activities of daily living
Several scales have been developed to measure what
many regard as the most important feature of Alzheimer’s
disease and where improvement will have a major positive
impact on the life of the patient and their carer.Scales that
measure ADL include the Progressive Deterioration Scale
(PDS, a 29-item assessment with a score of 1-100),
10 the
Interview for Deterioration in Daily living activities in
Dementia (IDDD),
11 and the Alzheimer’s Disease
Cooperative Study Activities of Daily Living Scale
(ADCS/ADL).
12 Measures of ADL need to be sufficiently
sensitive to assess activities over a range of severities,as
well as being a sensitive measure of change.
Global function
There are two types of global function scales.First,there
are those that capture the severity and stage of the disease
(ie,mild,moderate,and severe) and,second,those that
assess changes over the course of the illness.The Clinical
Dementia Rating (CDR)
13,14 measures the stage of
dementia over six domains (the sum of boxes and mem-
ory;orientation;judgment and problem solving;commu-
nity affairs;home and hobbies;personal care) and gives a
rating of questionable dementia (0.5),mild dementia (1),
moderate dementia (2), and severe dementia (3). The
Selected abbreviations and acronyms
ADAS-Cog Alzheimer’s Disease Assessment
Schedule–Cognitive Section
ADL activities of daily living
CDR Clinical Dementia Rating
CIBIC+ Clinicians’ Interview-based Impression of
Change–plus
IDDD Interview for Deterioration in Daily living
activities in Dementia
MMSE Mini-Mental State Examination
NMDA N-methyl-D-aspartate
NPI Neuropsychiatric InventoryGlobal Deterioration Scale (GDS)
15 gives a similar rating
of severity, but with an emphasis on the more severe
forms of disease.The concept of a global assessment of
change was developed to overcome the criticism that clin-
ical trials that only measured cognitive function were fail-
ing to capture (in a global sense) the changes that were
the most important to patients and their families.There
are a number of measures that have been developed,all
of which are based on the premise that if a clinician is able
to detect a change,then that change in itself is significant.
The basic format of the assessments is the same—a 7-
point scale with an anchor point in the middle for no
change and three measures of improvement and three
measures of deterioration (Clinical Global Impression of
Change
16). Some standardization has been introduced,
which has tended to improve the reliability of the mea-
sures (Clinicians’ Interview-based Impression of Change
[CIBIC]
17),but part of the validity is that the score reflects
the view of the individual rater,rather than being a scale
where answers are simply recorded onto a form.A devel-
opment is the introduction of information from the care-
giver,which allows the independent clinician marking the
scale to reflect changes that impinge on the patient and
their carer in a global sense (CIBIC+, which includes
information from the carer).
Pharmacological approaches to the manage-
ment of Alzheimer’s disease
Cholinesterase inhibitors
These drugs were introduced on the basis of ample neu-
rochemical evidence that there is a significant acetyl-
choline deficit in Alzheimer’s disease.One of the drugs’
main actions is to inhibit the enzyme acetyl-
cholinesterase, which breaks down acetylcholine, thus
effectively raising the level of the neurotransmitter.Four
drugs of this type have been established in Alzheimer’s
disease: tacrine, donepezil, rivastigmine, and galanta-
mine.They vary in their pharmacological action.Tacrine
is an acridine-based compound (its liver toxicity prob-
ably results from this),donepezil is piperidine based and
a selective acetylcholinesterase inhibitor, whereas
tacrine and galantamine have significant activity on
butyrylcholinesterase.Rivastigmine is a carbonate-based
compound and is relatively free of drug interactions,and
galantamine is an alkaloid. Donepezil has the longest
plasma half-life at about 70 hours compared with 6
hours for galantamine,3 hours for tacrine,and 1.5 hours
for rivastigmine (this has the practical advantage that it
is excreted quickly from the body and so relief from side
effects is much more speedy than with the longer-acting
compounds).The half-life also has implications for the
daily dosing regimen:the advantage of donepezil is that
it only needs to be given once a day.
Tacrine
This was the first drug to be introduced and, in many
ways, was the gold standard by which the others were
measured. The drug has positive effects on cognitive
function at dosages of 160 mg/day, and benefits have
been seen in terms of ADL and global function.
18,19
Unfortunately,almost half of all patients experience liver
side effects, usually a rise in transaminases, and so a
search began for an agent as effective as tacrine,but with-
out side effects.
Donepezil
As a piperidine-based compound, the introduction of
donepezil was important because of its lack of liver side
effects and the convenience of once-daily dosing. One
multinational study
20 involved patients in Australia,
Belgium, Canada, France, Germany, Ireland, New
Zealand,South Africa,and the UK.Eight hundred and
eighteen (818) patients were randomized to receive
placebo (n=274), 5 mg/day donepezil (n=271), or 10
mg/day donepezil (n=273).The mean age of patients was
just over 70 and they all satisfied the NINCDS/ADRDA
(National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer Disease and
Related Disorders Association)
21 criteria for probable
Alzheimer’s disease. Patients with mild-to-moderate
impairment were included, as assessed by an MMSE
score of between 10 and 26 and a CDR of 1 (mild) or 2
(moderate).The study lasted 30 weeks:24 weeks with a
double-blind,placebo-controlled phase followed by a sin-
gle-blind placebo washout over 6 weeks.Patients started
with 5 mg/day donepezil for 7 days followed by 10
mg/day.The positive effects on the ADAS-Cog are shown
in Figure 1.The percentage of patients rated as improved
was 21% for 5 mg/day,25% for 10 mg/day,and 14% for
placebo.The pattern of side effects (mostly related to the
digestive system, eg, diarrhea, nausea, and vomiting,
understandable in terms of the physiological effect of a
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37cholinergic drug) was the same (10%) for placebo and 5
mg/day of the drug,and double that in those taking the
higher dose.The IDDD was used to assess ADL and the
drug showed a protective effect against the decline and
activity that occurred with placebo.A similar USA-based
study
22 was in accordance with these findings and there
was evidence that the 10 mg/day dosage was superior to
the 5 mg/day dosage.
The longer-term efficacy and safety of donepezil has
been shown by an analysis of the continuation of the US
study.
23 In total,133 patients completed the trial,which
lasted nearly 5 years and showed that the rate of deteri-
oration in those taking the active drug was less than that
of placebo,that adverse events were mild and transient,
and that there was no evidence of liver toxicity.Winblad
et al reported a 12-month study in 286 patients in Nordic
countries in Europe.
24 Two thirds of the patients in the
donepezil and placebo group completed the study
(patients took 5 mg/day donepezil 28 days followed by
10 mg/day). Another study, also of a year’s duration,
examined the effects of donepezil in preserving function
over time.
25A predetermined definition of a decline in
functional status was operationalized and it was found
that those on the active drug were 5 months slower at
reaching this end point than those on placebo.This was
quantified as showing that the drug reduced the risk of
functional decline by 38% compared with placebo.The
effects of the drug have also been examined in people
with more severe Alzheimer’s disease
26 with 144 patients
randomized to donepezil and 146 to placebo over 24
weeks.Despite the severity of the illness,benefits were
seen in terms of global measures of change, cognitive
function, ADL, and psychiatric symptoms; 86% of
placebo patients completed the trial with 6% withdraw-
ing because of adverse events,compared with 84% and
8%,respectively,in those on active drug.
Rivastigmine
The effect of rivastigmine has been described in a US-
based study over 26 weeks in 699 patients with mild-to-
moderate Alzheimer’s disease.
27 Significant improve-
ments on the ADAS-Cog compared with placebo were
seen and these were particularly marked in those taking
a higher dosage (6-12 mg/day) An analysis of patients
with moderate and severe Alzheimer’s disease has shown
that the effects are as marked in this group of subjects
and it has been suggested that patients with comorbid
vascular disease gain a particular benefit.
28,29
Improvements have been seen in patients with advanced
dementia and behavioral disturbances using the NPI with
at least 50% of subjects improving by a third on the scale
and 44% being able to reduce or stop concurrent psy-
chotropic medication.
There were also significant benefits in ADL.A European
study assessed the safety and efficacy of two dosages of
rivastigmine (up to 4 mg/day and up to 12 mg/day) over
26 weeks.
30 In the rivastigmine group,24% had improved
compared with 16% in placebo by at least 4 points on the
ADAS-Cog;37% of people on rivastigmine compared
with 20% on placebo showed evidence of a global
improvement.Figure 2 shows these changes.
The effects of rivastigmine have also been demonstrated
in patients with dementia of the Lewy body type.
31 Patients
with this disorder appear to have a particularly profound
deficit in cholinergic function and the symptoms are char-
acterized by significant psychiatric symptoms and behav-
ioral disturbances.One hundred and twenty (120) patients
who satisfied standard criteria for Lewy body dementia
(the vast majority having fluctuating cognitive function
and recurrent visual hallucinations) were recruited in the
UK,Spain,and Italy (92 completed the study).Treatment
started with 1.5 mg rivastigmine or placebo twice a day,
increasing by 1.5 mg twice a day, for 2 weeks until 12
mg/day or a maximum well-tolerated maintenance dosage
Pharmacological aspects
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Figure 1. Effect of donepezil, 5 and 10 mg/day, and placebo on Alzheimer’s
Disease Assessment Schedule–Cognitive Section (ADAS-Cog)
scores. Data are least square means±SE.  *P<0.0001; **P=0.0005;
***P=0.0002; 
#P=0.0315; 
##P=0.0021.
Reproduced from reference 20: Burns A, Rossor M, Hecker J, et al. The effects of
donepezil in Alzheimer’s disease: results from a multinational trial. Dementia Cognitive
Geriatr Disord. 1999;10:237-244. Copyright © 1999, Karger.
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##was reached.The primary efficacy measure was a reduc-
tion in scores on the NPI. Results showed significant
improvement over the course of the study,with evidence
of some benefit on the global functioning.
Galantamine
Galantamine has a somewhat novel,dual mode of action
in that,in addition to its anticholinesterase activity,it has
a modulating effect on nicotinic acetylcholine receptors
in the brain,which seem to have a role in potentiating the
response to acetylcholine. In Europe and Canada,
Wilcock
32 reported a 6-month study of 653 patients with
mild-to-moderate Alzheimer’s disease, who were ran-
domly assigned to either placebo or a maintenance
dosage of galantamine of 24 or 32 mg/day.At 6 months,
improvements in ADL and on the CIBIC+ were
recorded. Raskind et al
33 reported on a 6-month, ran-
domized,placebo-controlled trial followed by a 6-month
extension.Patients with mild-to-moderate Alzheimer’s
disease (n=636) were assigned to either placebo or an
escalating dosage of 24 or 32 mg/day galantamine, fol-
lowed by a 6-month,open-label study with 24 mg/day.The
conclusion was that at 24 mg/day,the drug is effective and
safe in improving cognitive function and global function
(Figure 3) over 6 months,and maintaining that improve-
ment at 12 months.A total of 978 patients were enrolled
in a relatively slow escalation study described by Tariot et
al.
34A 4-week,placebo run-in was concluded with patients
being randomized to receive placebo or 8, 16, or 24
mg/day galantamine.After 5 months, those on galanta-
mine showed improvement on the ADAS-Cog, the
CIBIC+,a number of psychiatric symptoms,and ADL.
Adverse events resulting in discontinuation from the trial
were found in 10% of the galantamine group and 7% of
the placebo group. Coyle and Kershaw
35 carried out an
analysis of the extension studies of galantamine and
found that patients who had been treated with 24 mg/day
throughout the trials had better cognitive function com-
pared with those on placebo.The suggestion that stabi-
lization occurs would be in keeping with the additional
nicotinic receptor modulation activity of the drug.
What is the difference between the anticholinesterase
drugs?
There are currently direct comparison (head-to-head) tri-
als taking place to compare the three anticholinesterase
drugs (tacrine is no longer marketed).Each drug has its
own advantages and disadvantages,but these are often
only in terms of theoretical differences reflected in the
marketing of individual drugs and represent a particular
interest or scale that has been used by investigators.For
example,because of its long half-life,donepezil can be
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Figure 2. The effects of rivastigmine, 1 and 4 mg/day, and 6 and 12
mg/day compared with placebo on Alzheimer’s Disease
Assessment Schedule–Cognitive Section (ADAS-Cog). *P<0.05
compared with placebo.
Reproduced from reference 30: Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and
safety of rivastigmine in patients with Alzheimer’s disease: international randomised
controlled trial. BMJ. 1999;318:633-638. Copyright © 1999, BMJ.
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Reproduced from reference 34: Tariot PN, Solomon PR, Morris JC, et al. A 5-month
randomized, placebo-controlled trial of galantamine in Alzheimer’s disease. Neurology.
2000;54:2269-2276. Copyright © 2000, Lippincott, Williams and Wilkins.
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Double-blind Open-extensionprescribed once a day.It has been suggested that galant-
amine delays the onset of behavioral problems and psy-
chiatric symptoms in dementia.Rivastigmine seems to
have fewer drug interactions
36 and has been shown to be
effective in dementia with Lewy bodies.
With regard to improvement in cognitive function,com-
parison of the rates shows that the difference between
the ADAS-Cog and placebo in the trials are 4.1 points
for tacrine, 2.5 and 2.9 points for 5 and 10 mg/day
donepezil,respectively,4.9 points for rivastigmine (8.0
points for patients taking between 6 and 12 mg/day with
moderately severe to severe Alzheimer’s disease; 6.2
points for those with Alzheimer’s disease and comorbid
vascular risk factors),and 3.8 and 3.9 points,respectively,
for 32 and 24 mg/day galantamine.
The commonest adverse events are nausea, vomiting,
diarrhea,anorexia,and dizziness.Rates are between 5%
and 15%.There is evidence to suggest that rivastigmine
and galantamine (particularly at higher doses) are more
likely to induce nausea,vomiting,and diarrhea as well as
dizziness, although generally speaking, the longer the
titration time, the smaller the number of side effects
(something that agrees with clinical practice
37).
Noncholinergic approaches
Glutamatergic antagonists
Glutamate is a hitherto relatively neglected excitatory
neurotransmitter in the brain and is probably present in
70% of neurones.A number of different receptor types are
involved,one of particular relevance to Alzheimer’s dis-
ease being the N-methyl-D-aspartate (NMDA) receptor.
These receptors appear to have a specific role in the plas-
ticity of neurones and therefore a specific function in terms
of the formation of memories and learning.In excess,glu-
tamate is excitotoxic and activates NMDA receptors.
There is evidence that glutamate may be involved in the
pathological process of Alzheimer’s disease and its pres-
ence seems to stimulate the deposition of β-amyloid.
Drugs that have a high affinity for NMDA produce side
effects including schizophreniform psychoses,but those
that have lower receptor antagonist affinity seem only to
have an influence in pathological conditions.
The most widely studied of these drugs is memantine.
Several double-blind studies in the early 1990s suggested
a role for the drug in dementia, but more recently a
European-based study and a USA-based study have
shown the drug to be effective in people with moderately
severe to severe Alzheimer’s disease.Two studies suggest
that it is effective in people with vascular dementia.The
drug currently has a license under European regulations
for the treatment of moderately severe to severe
Alzheimer’s disease, making it stand apart from the
cholinesterase drugs.Significant improvements in global
ratings of dementia, ADL, and cognitive function (as
assessed by the Severe Impairment Battery) have been
demonstrated for dosages of 10 or 20 mg/day (escalating
from 5 mg/day over 1 week).The results of the clinical
global impression ratings appear in Figure 4.
38 Open-label
studies at the end of the double-blind phases have demon-
strated that improvements can still occur when there is a
delay to the initiation of treatment.The side effects of the
drug tend to be quite minor,the commonest being dizzi-
ness,but confusion and hallucinations are commoner in
the group taking the active drug.Agitation is much com-
moner in people on placebo.Memantine has been used in
Germany for many years and so a significant body of
safety data is available.
38Whether the drug will be suitable
for people with mild-to-moderate dementia,whether it will
have a significant action against vascular dementia,and
whether treatment in combination with cholinesterase
drugs are effective strategies remain to be evaluated.
Estrogen
Estrogen has positive and beneficial effects on the brain
in a number of areas.
39There is good evidence from epi-
demiological work that postmenopausal women are pro-
tected against the development of Alzheimer’s disease if
Pharmacological aspects
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Figure 4. Results of global rating of change in patients on memantime.
38
*P=0.001; **P=0.006. ITT, intention-to-treat.
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Results in clinical global impression ratingsthey are taking estrogen.The evidence so far that estrogen
itself helps the symptoms of Alzheimer’s disease is less
clear cut.The results from different studies appear to be
contradictory:while some studies suggest that there is no
benefit,
40-42Asthana et al
43 have reported that estradiol may
produce improvements.In a prospective study,Zandi et
al
44 found that women who used hormone replacement
therapy (HRT) had a lower incidence of Alzheimer’s dis-
ease over 3 years’ follow-up than nonusers.The distinct
relationship between Alzheimer’s disease risk and dura-
tion of HRT observed in this study highlights the need for
continued research into the optimal regimen,dosage,and
timing of HRT for possible neuroprotection. Although the
combined estrogen-progestin arm of the Women’s Health
Initiative randomized trial was terminated due to a spe-
cific risk–benefit profile for a specific therapeutic regimen,
the risk–benefit profile may well change if new studies
confirmed these results.
Statins
Epidemiological studies have suggested that people on
statins have a lower rate of Alzheimer’s disease com-
pared with those not taking the drugs.
45 There is good
biochemical evidence to postulate why statins may be of
benefit,not least in their role in reducing the influence of
vascular risk factors on the degree of cognitive impair-
ment.It may be that statins are of some benefit even if
the serum cholesterol is normal.
46,47There is insufficient
evidence at this stage for the prescription of these drugs
solely for an anti-Alzheimer’s effect.
Ginkgo biloba
One published study
48 suggested a beneficial effect of
Ginkgo biloba over placebo in people with dementia.
However,the effects,while significant,are marginal and
are not as persuasive as for the anticholinesterase drugs.
Because Ginkgo biloba can be bought over the counter,
it remains something that patients, sometimes encour-
aged by their carers,will take to alleviate the symptoms
of dementia.Individuals often report a beneficial effect.
Other approaches
There is good evidence that oxidative damage occurs in
Alzheimer’s disease and so intervention with an anti-
oxidant may prove to be of benefit in people with
Alzheimer’s disease.One study has suggested that vitamin
E delays the progression of Alzheimer’s disease
49 and sev-
eral reports have now documented that high levels of
homocysteine (reflecting,probably poor intake of vitamins
B12 and folate) are associated with Alzheimer’s disease.
50,51
Vitamin C may also have some benefit in protection
against Alzheimer’s disease.However,the antioxidant vit-
amin taken seems to reduce the incidence of the disease,
particularly those including vitamin E.
52,53There was much
publicity recently when a vaccine was introduced for
Alzheimer’s disease,which potentially had an antiamyloid
effect.
54 However, clinical studies have been suspended
because some patients in these two trials developed
inflammation of the central nervous system.Recent neg-
ative publicity in the UK surrounding the combined
measles,mumps,and rubella (MMR) vaccine has proba-
bly had the effect of directing public enthusiasm away
from vaccinations.
As case-control studies become more popular and epi-
demiological databases,which document risk factors,can
easily be interrogated,the number of other risk—or pro-
tective—factors for Alzheimer’s disease being described
has increased.Mental and physical exercise is protective,
55
red wine is protective,
56 moderate alcohol intake of any
type seems to be of benefit,and,most recently,drinking
coffee appears to reduce the rate of Alzheimer’s disease.
57
One specific study looked at the control of blood pressure
and showed that rates of dementia can be significantly
reduced in this way.
58 Chelation of metals may also have a
beneficial effect.Translating the epidemiological findings
into things that will change people’s lifestyles,or even sug-
gest a treatment strategy,is a long way off.
Conclusion
A number of drugs are now available that can improve
the symptoms of Alzeheimer’s disease.The most consis-
tent benefits have been demonstrated with the anti-
cholinesterase drugs.Their efficacy in mild-to-moderate
Alzheimer’s disease has been documented, but their
effects on more severe dementia and other dementias
such as vascular dementia and Lewy body dementia are
being tried. Memantine is a new agent that holds
promise,not least because it acts on a different neuro-
transmitter system.A trial of adding drugs together has
yet to be tried,but no doubt will be.The armamentarium
with which the clinician has to fight Alzheimer’s disease
has never been greater. ❏ 
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El tratamiento del deterioro cognitivo en la
Enfermedad de Alzheimer
En la Enfermedad de Alzheimer, ahora los aspectos
cognitivos responden a diversas drogas. Los antico-
linesterásicos apuntan al déficit de acetilcolina. En la
Enfermedad de Alzheimer leve a moderada estos
fármacos proveen beneficios significativos respecto
al placebo en la sección cognitiva de la Escala de
Evaluación de la Enfermedad de Alzheimer (ADAS-
Cog). Los efectos colaterales, en un 5% a 15% de los
casos, incluyen náuseas, vómitos, diarrea, anorexia y
mareos.  La tacrina, el anticolinesterásico guía, pro-
vocó un aumento frecuente de las enzimas hepáti-
cas y fue retirada; el donepezil administrado una vez
al día no afecta el hígado y mejora las mediciones
globales de cambio en la demencia severa; la rivas-
tigmina está indicada en la enfermedad vascular
comórbida, mientras que la galantamina modula los
receptores nicotínicos de acetilcolina cerebral, los
que potencian la respuesta a acetilcolina. Entre los
agentes alternativos se incluyen los antagonistas del
receptor  N-metil-D-aspartato (NMDA), como la
memantina, que obtuvo la licencia en Europa para
la Enfermedad de Alzheimer moderadamente
severa a severa; actúa en un sistema neurotransmi-
sor diferente, presente en el 70% de las neuronas,
que al proteger contra la activación glutamatérgica
patológica  preserva o aun restaura la activación glu-
tamatérgica fisiológica. El arsenal del clínico en la
Enfermedad de Alzheimer nunca ha sido más nume-
roso.
Traitement du déficit cognitif au cours de la
maladie d’Alzheimer
La cognition, atteinte au cours de la maladie
d’Alzheimer, répond maintenant à plusieurs médi-
caments. Les anticholinestérasiques ciblent le déficit
en acétylcholine. Au cours de la maladie d’Alzheimer
légère à modérée, ils procurent tous un bénéfice
significatif comparés au placebo sur l’échelle ADAS-
Cog (Alzheimer’s Disease Assessment Schedule-
Cognitive Section, échelle de mesure de la perfor-
mance cognitive). Les effets secondaires, dans 5 % à
15 % des cas, incluent nausées, vomissements, diar-
rhée, anorexie et vertiges. La tacrine, le principal
anticholinestérasique, provoquait souvent une élé-
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marché ; en dose unique quotidienne, le donépézil
respecte le foie et améliore les mesures globales de
détérioration dans la démence sévère ; la rivastig-
mine est indiquée en cas de comorbidité avec la
maladie vasculaire ; enfin, la galantamine agit sur les
récepteurs cérébraux nicotiniques de l’acétylcholine
qui potentialisent la réponse à l’acétylcholine. Parmi
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récepteur du N-méthyl-D-aspartate (NMDA), la
mémantine, autorisée en Europe dans le traitement
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